Table 1. Key characteristics of 15 RCTs between 2012 and 2019.
| Number of RCTs | ||
|---|---|---|
| n | % | |
| Total number of reviewed RCTs | 15 | 100 |
| Number with HRQOL as primary endpoint | 0 | 0 |
| Number with HRQOL as secondary endpoint | 9 | 60 |
| Number with HRQOL as exploratory endpoint | 5 | 33 |
| Number with additional HRQOL publication | 13 | 87 |
| Number discussing HRQOL in the main publication | 7 | 47 |
| Multi-country locations | 15 | 100 |
| Industry funded | 15 | 100 |
| Type of ICI* | ||
| Atezolizumab | 1 | 7 |
| Avelumab | 0 | 0 |
| Durvalumab | 0 | 0 |
| Ipilimumab | 5 | 33 |
| Ipilimumab + Nivolumab | 2 | 13 |
| Nivolumab | 7 | 47 |
| Pembrolizumab | 4 | 27 |
| Non-checkpoint inhibitor controls | 12 | 80 |
| Chemotherapy | 8 | 53 |
| Placebo | 1 | 7 |
| Everolimus | 1 | 7 |
| GP100 | 1 | 7 |
| Sunitinib | 1 | 7 |
| Type of cancer | ||
| Melanoma | 8 | 53 |
| Non-Small Cell Lung Cancer | 3 | 20 |
| Squamous Cell Carcinoma of the Head and Neck | 1 | 7 |
| Advanced renal cell carcinoma | 2 | 13 |
| Urothelial cancer | 1 | 7 |
| Sample size | ||
| 272 to 500 | 5 | 33 |
| 501 to 800 | 5 | 33 |
| 801 to 951 | 5 | 33 |
| Peer-reviewed clinical journals | ||
| N Engl J Med (IF = 72.406) | 1 | 7 |
| Lancet Oncol (IF = 33.900) | 5 | 33 |
| J Clin Oncol (IF = 26.303) | 2 | 13 |
| Ann Oncol (IF = 11.855) | 1 | 7 |
| J Thorac Oncol (IF = 6.595) | 1 | 7 |
| Eur J Cancer (IF = 6.029) | 3 | 20 |
| Clin Lung Cancer (IF = 3.66) | 1 | 7 |
| Health Qual Life Outcomes (IF = 2.143) | 1 | 7 |
RCTs = randomised controlled trials. HRQOL = health-related quality of life. ICI = immune checkpoint inhibitors.
* = Some RCTs used more than one ICI.